Vanguard Group
BDTX icon

Vanguard Group’s Black Diamond Therapeutics BDTX Stock Holding History

Vanguard Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.32M Hold
2,188,857
– – ﹤0.01% 3231
2025
Q3 		$8.3M Buy
2,188,857
+85,825
+4% +$251K ﹤0.01% 3068
2025
Q2 		$5.22M Sell
2,103,032
-253,801
-11% -$489K ﹤0.01% 3205
2025
Q1 		$3.65M Sell
2,356,833
-57,108
-2% -$120K ﹤0.01% 3285
2024
Q4 		$5.17M Buy
2,413,941
+95,930
+4% +$275K ﹤0.01% 3261
2024
Q3 		$10.1M Buy
2,318,011
+186,387
+9% +$1.01M ﹤0.01% 2954
2024
Q2 		$9.93M Buy
2,131,624
+226,324
+12% +$1.21M ﹤0.01% 2930
2024
Q1 		$9.66M Sell
1,905,300
-41,793
-2% -$169K ﹤0.01% 2975
2023
Q4 		$5.47M Sell
1,947,093
-16,490
-0.8% -$38.7K ﹤0.01% 3251
2023
Q3 		$5.64M Buy
1,963,583
+482,198
+33% +$1.78M ﹤0.01% 3199
2023
Q2 		$7.48M Buy
1,481,385
+723,800
+96% +$1.48M ﹤0.01% 3112
2023
Q1 		$1.43M Hold
757,585
– – ﹤0.01% 3793
2022
Q4 		$1.36M Buy
757,585
+487
+0.1% +$877 ﹤0.01% 3803
2022
Q3 		$1.28M Buy
757,098
+92,141
+14% +$284K ﹤0.01% 3922
2022
Q2 		$1.64M Sell
664,957
-11,730
-2% -$27.3K ﹤0.01% 3894
2022
Q1 		$1.88M Sell
676,687
-338,104
-33% -$1.23M ﹤0.01% 3986
2021
Q4 		$5.41M Sell
1,014,791
-85,032
-8% -$594K ﹤0.01% 3562
2021
Q3 		$9.3M Sell
1,099,823
-460,636
-30% -$4.55M ﹤0.01% 3282
2021
Q2 		$19M Sell
1,560,459
-315,526
-17% -$6.24M ﹤0.01% 2871
2021
Q1 		$45.5M Buy
1,875,985
+30,023
+2% +$810K ﹤0.01% 2371
2020
Q4 		$59.2M Buy
1,845,962
+221,810
+14% +$7.29M ﹤0.01% 2115
2020
Q3 		$49.1M Buy
1,624,152
+788,646
+94% +$24M ﹤0.01% 2027
2020
Q2 		$35.2M Buy
835,506
+202,540
+32% +$7.45M ﹤0.01% 2177
2020
Q1 		$15.8M Buy
+632,966
New +$19.3M ﹤0.01% 2397

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Vanguard Group's BDTX Position: Q4 2025 in Review

Vanguard Group held its Black Diamond Therapeutics (BDTX) position steady in Q4 2025 at 2,188,857 shares worth $5.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3231.

Vanguard Group first reported a position in BDTX in Q1 2020 and has held it in 24 quarters since. The position peaked at $59.2M in Q4 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q4 2025.

  • Vanguard Group held 2,188,857 shares of Black Diamond Therapeutics worth $5.32M as of Q4 2025.
  • Vanguard Group left its Black Diamond Therapeutics share count unchanged in Q4 2025.
  • Black Diamond Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3231 holding.
  • Vanguard Group first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Vanguard Group's Black Diamond Therapeutics position peaked at $59.2M in Q4 2020.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.